Patents by Inventor Matthew Duncan HELM

Matthew Duncan HELM has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USP7 INHIBITOR FOR USE IN THE TREATMENT OF CANCER
    Publication number: 20230088286
    Abstract: Provided herein are treatments for cancer by inhibition of USP7 activity, for example inhibition of USP7 activity in fibroblasts, inhibition of extra-cellular matrix remodelling in the tumour microenvironment, inhibition of VEGF, inhibition of angiogenesis or metastasis, modulation of the immune system, or a combination thereof.
    Type: Application
    Filed: February 12, 2021
    Publication date: March 23, 2023
    Inventors: Xavier JACQ, Ian Thomas LOBB, Mark WAPPETT, Anamarija JURISIC, James Samuel Shane ROUNTREE, Matthew Duncan HELM
  • PHARMACEUTICAL COMPOUNDS AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19)
    Publication number: 20220033397
    Abstract: Provided are USP19 inhibitors, methods of treating obesity, metabolic syndrome and/or diabetes using the USP19 inhibitor compounds, as well as those compounds for use in methods of treating obesity, metabolic syndrome and/or diabetes. Also provided are methods of treating muscular atrophy, for example cachexia or sarcopenia with USP19 inhibitor compounds, plus those a compounds for use in methods of treating muscular atrophy.
    Type: Application
    Filed: December 6, 2019
    Publication date: February 3, 2022
    Inventors: James Samuel Shane ROUNTREE, Steven Kristopher WHITEHEAD, Adam Piotr TREDER, Lauren Emma PROCTOR, Steven David SHEPHERD, Frank BURKAMP, Joana Rita Castro COSTA, Colin O'DOWD, Timothy HARRISON, Matthew Duncan HELM, Ewelina ROZYCKA, Aaron CRANSTON, Xavier JACQ
  • USP19 INHIBITORS FOR USE IN THERAPY
    Publication number: 20220016115
    Abstract: Provided are USP19 inhibitors, methods of treating obesity, metabolic syndrome and/or diabetes using the USP19 inhibitor compounds, as well as those compounds for use in methods of treating obesity, metabolic syndrome and/or diabetes. Also provided are methods of treating muscular atrophy, for example cachexia or sarcopenia with USP19 inhibitor compounds, plus those compounds for use in methods of treating muscular atrophy.
    Type: Application
    Filed: December 6, 2019
    Publication date: January 20, 2022
    Inventors: James Samuel Shane ROUNTREE, Peter HEWITT, Mary Melissa MCFARLAND, Frank BURKAMP, Christina BELL, Colin O'DOWD, Timothy HARRISON, Matthew Duncan HELM, Ewelina ROZYKA, Aaron CRANSTON, Xavier JACQ, Lauren PROCTOR
  • PHARMACEUTICAL COMPOUNDS
    Publication number: 20220002264
    Abstract: The present invention relates to compounds of Formula (I) that are useful as inhibitors of the activity of the ubiquitin specific protease USP19. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in therapy.
    Type: Application
    Filed: July 6, 2021
    Publication date: January 6, 2022
    Inventors: Peter HEWITT, Mary Melissa MCFARLAND, James Samuel Shane ROUNTREE, Frank BURKAMP, Christina BELL, Lauren PROCTOR, Matthew Duncan HELM, Colin O'DOWD, Timothy HARRISON
  • Pharmaceutical compounds
    Patent number: 11053213
    Abstract: The present invention relates to compounds of Formula (I) that are useful as inhibitors of the activity of the ubiquitin specific protease USP19. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in therapy.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: July 6, 2021
    Assignee: ALMAC DISCOVERY LIMITED
    Inventors: Peter Hewitt, Mary Melissa McFarland, James Samuel Shane Rountree, Frank Burkamp, Christina Bell, Lauren Proctor, Matthew Duncan Helm, Colin O'Dowd, Timothy Harrison
  • PHARMACEUTICAL COMPOUNDS
    Publication number: 20190233394
    Abstract: The present invention relates to compounds of Formula (I) that are useful as inhibitors of the activity of the ubiquitin specific protease USP19. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in therapy.
    Type: Application
    Filed: July 26, 2017
    Publication date: August 1, 2019
    Applicant: Almac Discovery Limited
    Inventors: Peter HEWITT, Mary Melissa MCFARLAND, James Samuel Shane ROUNTREE, Frank BURKAMP, Christina BELL, Lauren PROCTOR, Matthew Duncan HELM, Colin O'DOWD, Timothy HARRISON